CTOs on the Move

Milestone Scientific

www.milestone.com

 
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone`s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone`s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.milestone.com
  • 425 Eagle Rock Avenue Suite 403
    Roseland, NJ USA 07068
  • Phone: 973.535.2717

Executives

Name Title Contact Details

Similar Companies

InTouch Health

InTouch Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

bioTheranostics

bioTheranostics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kestra Medical Technologies

Kestra Medical Technologies is a venture backed, medical device start up company located in Washington State providing innovative, intuitive medical technologies to protect and support at-risk patients.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

Keystone Dental

Keystone Dental is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.